Advances in treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current recommendations, clinical trials, and real-word data.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of rare, autoimmunologic diseases that can manifest as a vital organ- and / or life‑threatening disorder. They are classified as small‑vessel vasculitis. Inflammatory infiltrations cause destruction and necrosis of the vessel wall, as well as occlusion of the vessel lumen; thus, organs supplied by these vessels become ischemic and damaged. According to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature, AAV comprises 3 distinct diseases, but this review focuses on granulomatosis with polyangiitis and microscopic polyangiitis. Quick diagnosis and prompt initiation of intensive immunosuppressive therapy are crucial to prevent an unfavorable outcome in patients with AAV. Recent years have brought development in therapeutic strategies, new immunosuppressive agents, and future perspectives. Our review starts with the description of current diagnostic and long‑term follow‑up strategies, including the role of ANCA, immunoglobulin G, and CD19/CD20 cell monitoring, as well as remission assessment. The following sections present possible induction and maintenance therapies, including cyclophosphamide, rituximab, glucocorticoids, avacopan, and therapeutic plasma exchange, based on current recommendations ofthe European Alliance of Associations for Rheumatology, Kidney Disease: Improving Global Outcomes, and British Society of Rheumatology, as well as results of recent randomized controlled trials and real‑world data. These therapies are particularly relevant for specific clinical conditions, such as rapidly progressive glomerulonephritis and / or pulmonary hemorrhage. We describe in detail a new, promising molecule, avacopan, which acts by blocking the C5a receptor on neutrophils and other cell types. Avacopan is currently approved by the Food and Drug Administration and the European Medicines Agency but rigorous liver function monitoring-specifically the activity of alanine aminotransferase and aspartate aminotransferase and bilirubin level-before and during the treatment course is required to ensure the safe delivery of this steroid-sparing therapy. Recently, in April 2026 the Food and Drug Administration proposed to withdraw approval for avacopan due to, among others, a lack of substantial evidence of effectiveness for the drug.